Neurobiology of Trauma and MDMA for PTSD

Psychologist Jim Hopper and I discuss the neurobiology of trauma, MDMA-assisted therapy for PTSD, the critical role embodied treatment modalities play in trauma healing, and use of Buddhist psychology and Internal Family Systems (IFS) for trauma resolution. He fully explicates the process used in the FDA-approved and MAPS-sponsored MDMA phase 3 trials, discusses the results, and clarifies for whom MDMA, Ketamine or psilocybin sessions could be adjunctive trauma treatment. We also discuss a habit model of understanding trauma response as well as an updated ethical view of addiction. Jim is a consummate communicator. That, coupled with his depth and breadth of knowledge about trauma therapy, make this episode a critical listen for every clinician working in the trauma field. 

JIm's website

Jim's publications

Jim Hopper, PhD is most often sought for his expertise on the neurobiology of trauma and sexual assault, and on the unique experiences and needs of males who have experienced sexual abuse or sexual assault. He trains others in contemplative practices that transform the brain to bring healing and genuine happiness, and is co-editor of Mindfulness-Oriented Interventions for Trauma: Integrating Contemplative Practices. He is a sub-investigator at the Boston site of the FDA-approved and MAPS-sponsored phase 3 trial of MDMA-Assisted Therapy for PTSD. Jim is a Teaching Associate in Psychology in the Department of Psychiatry of Harvard Medical School, and a consultant to the Outpatient Addictions Service of the Cambridge Health Alliance.